Pulmonx/LUNG

$7.59

-3.8%
-
1D1W1MYTD1YMAX

About Pulmonx

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.

Ticker

LUNG

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Steven Williamson

Employees

279

Headquarters

Redwood city, United States

Pulmonx Metrics

BasicAdvanced
$306.23M
Market cap
-
P/E ratio
-$1.60
EPS
0.64
Beta
-
Dividend rate
$306.23M
0.63851
$14.84
$7.72
548.96K
6.496
5.773
29.657
31.479
-32.76%
-44.68%
-36.9%
4.459
2.569
2.641
27.98%
-0.9%
28.02%

What the Analysts think about Pulmonx

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
113.44% upside
High $17.00
Low $14.00
$7.59
Current price
$16.20
Average price target

Pulmonx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-71.87% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$19.2M
9.09%
Net income
$-13.8M
-7.38%
Profit margin
-71.87%
-15.1%

Pulmonx Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.58%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.42
-$0.43
-$0.39
-$0.36
-
Expected
-$0.44
-$0.44
-$0.43
-$0.41
-$0.46
Surprise
-4.55%
-1.56%
-8.84%
-11.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Pulmonx stock?

Pulmonx (LUNG) has a market cap of $306.23M as of April 15, 2024.

What is the P/E ratio for Pulmonx stock?

The price to earnings (P/E) ratio for Pulmonx (LUNG) stock is 0 as of April 15, 2024.

Does Pulmonx stock pay dividends?

No, Pulmonx (LUNG) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Pulmonx dividend payment date?

Pulmonx (LUNG) stock does not pay dividends to its shareholders.

What is the beta indicator for Pulmonx?

Pulmonx (LUNG) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Pulmonx stock price target?

The target price for Pulmonx (LUNG) stock is $16.2, which is 116.58% above the current price of $7.48. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Pulmonx stock

Buy or sell Pulmonx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing